Bartłomiej Kisiel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bartłomiej Kisiel has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
- Rafał Płoski
Department of Medical Genetics, Medical University of Warsaw, 02-106 Warsaw, Poland
11 shared publications - Witold Tłustochowicz
Department of Internal Medicine and Rheumatology, Military Institute of Medicine, National Research Institute, Warsaw, Poland
11 shared publications Witold Tłustochowicz
Department of Internal Diseases and Rheumatology, Military Institute of Medicine, Szaserów 128, 04-141, Warsaw, Poland
7 shared publicationsArtur Bachta
6 shared publications- Małgorzata Tłustochowicz
Department of Internal Diseases and Rheumatology, Military Institute of Medicine, 04-141 Warsaw, Poland
6 shared publications - Krzysztof Kłos
Department of Battlefield Medicine, Military Institute of Medicine – National Research Institute, Warsaw, Poland
5 shared publications
Latest Publications
- Open Access
- 19 October 2026
- Published by Medical Communications Sp. z.o.o. in Pediatria i Medycyna Rodzinna
- Vol. 22 (3) , 163
Pathological vertebral fracture secondary to spinal echinococcosis. A case report
Background: Spinal osteoparasitoses caused by Echinococcus granulosus are rare and diagnostically challenging due to sterile cultures, similarity to bacterial spondylodiscitis, and poor response to antibiotic therapy. This study aimed to present a case of Th12–L1 vertebral body involvement and evaluate the diagnostic pathway and treatment effectiveness. Case presentation: A patient presented with localised back pain without neurological deficit, which contributed to delayed diagnosis. Over five months, progressive vertebral destruction, paravertebral abscess formation, and fistula development occurred despite empirical antibiotic therapy. Serological testing revealed an elevated titre of anti-Echinococcus IgG antibodies, confirming the diagnosis. Albendazole therapy (2 × 400 mg daily) was initiated. Four surgical procedures were performed, including stabilisation, abscess drainage, vacuum-assisted closure therapy, and fistulotomy. Conclusions: Parasitic infection should be considered in spinal lesions with sterile cultures and poor response to antibiotics. Multidisciplinary management is essential for accurate diagnosis and effective treatment.
- 19 October 2026
- Published by Medical Communications Sp. z.o.o. in Pediatria i Medycyna Rodzinna
- Vol. 22 (3) , 163
Open AccessPathological vertebral fracture secondary to spinal echinococcosis. A case report
Background: Spinal osteoparasitoses caused by Echinococcus granulosus are rare and diagnostically challenging due to sterile cultures, similarity to bacterial spondylodiscitis, and poor response to antibiotic therapy. This study aimed to present a case of Th12–L1 vertebral body involvement and evaluate the diagnostic pathway and treatment effectiveness. Case presentation: A patient presented with localised back pain without neurological deficit, which contributed to delayed diagnosis. Over five months, progressive vertebral destruction, paravertebral abscess formation, and fistula development occurred despite empirical antibiotic therapy. Serological testing revealed an elevated titre of anti-Echinococcus IgG antibodies, confirming the diagnosis. Albendazole therapy (2 × 400 mg daily) was initiated. Four surgical procedures were performed, including stabilisation, abscess drainage, vacuum-assisted closure therapy, and fistulotomy. Conclusions: Parasitic infection should be considered in spinal lesions with sterile cultures and poor response to antibiotics. Multidisciplinary management is essential for accurate diagnosis and effective treatment.
- Open Access
- 30 May 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6) , 120
Comparable effectiveness of intensive intravenous and less intensive immunosuppressive treatment in retroperitoneal fibrosis: a retrospective real-world cohort study
Retroperitoneal fibrosis (RPF) is a rare fibro-inflammatory disease frequently complicated by ureteral obstruction and renal impairment. Due to its rarity, heterogeneous clinical course, and the absence of standardized treatment guidelines, optimal immunosuppressive management of RPF remains uncertain. This study aimed to evaluate the real-world effectiveness and safety of different immunosuppressive treatment strategies in patients with RPF. A retrospective, single-center observational study was conducted including patients with idiopathic or immune-mediated RPF treated between 2010 and 2025. Patients were grouped according to treatment strategy: intensive intravenous therapy with cyclophosphamide or rituximab, or less intensive oral immunosuppressive therapy including methotrexate, mycophenolate mofetil or azathioprine. Treatment effectiveness was assessed using a composite endpoint incorporating clinical, laboratory and radiological response. Secondary outcomes included renal function, relapse, treatment safety, and glucocorticoid exposure. Twenty-nine patients were included in the analysis, of whom 11 received intensive therapy and 18 were treated with less intensive oral immunosuppressive regimens. Overall treatment effectiveness was achieved in 68% of evaluable patients and did not differ significantly between groups (OR 2.67, 95% CI 0.41–17.17). Clinical, laboratory, and radiological responses did not differ significantly between treatment groups. Hydronephrosis resolved in 75% of affected patients. Median serum creatinine levels improved during follow-up in both treatment groups, without significant intergroup differences at last observation (1.20 mg/dL [1.10–1.30] vs. 1.20 mg/dL [0.80–1.40]). The median relative reduction in periaortic mass thickness was 41.2% (24.45–53.95). No significant differences in overall safety outcomes were observed. In this real-world cohort of patients with RPF, intensive intravenous immunosuppressive regimens were not associated with superior treatment effectiveness compared with less intensive oral therapies. These findings support an individualized approach to treatment selection in RPF, taking disease severity, renal involvement and patient-specific factors into account. Prospective studies in larger cohorts are needed to further define optimal long-term management strategies for this rare disease.
- 30 May 2026
- Published by Springer Nature in Rheumatology International
- Vol. 46 (6) , 120
Open AccessComparable effectiveness of intensive intravenous and less intensive immunosuppressive treatment in retroperitoneal fibrosis: a retrospective real-world cohort study
Retroperitoneal fibrosis (RPF) is a rare fibro-inflammatory disease frequently complicated by ureteral obstruction and renal impairment. Due to its rarity, heterogeneous clinical course, and the absence of standardized treatment guidelines, optimal immunosuppressive management of RPF remains uncertain. This study aimed to evaluate the real-world effectiveness and safety of different immunosuppressive treatment strategies in patients with RPF. A retrospective, single-center observational study was conducted including patients with idiopathic or immune-mediated RPF treated between 2010 and 2025. Patients were grouped according to treatment strategy: intensive intravenous therapy with cyclophosphamide or rituximab, or less intensive oral immunosuppressive therapy including methotrexate, mycophenolate mofetil or azathioprine. Treatment effectiveness was assessed using a composite endpoint incorporating clinical, laboratory and radiological response. Secondary outcomes included renal function, relapse, treatment safety, and glucocorticoid exposure. Twenty-nine patients were included in the analysis, of whom 11 received intensive therapy and 18 were treated with less intensive oral immunosuppressive regimens. Overall treatment effectiveness was achieved in 68% of evaluable patients and did not differ significantly between groups (OR 2.67, 95% CI 0.41–17.17). Clinical, laboratory, and radiological responses did not differ significantly between treatment groups. Hydronephrosis resolved in 75% of affected patients. Median serum creatinine levels improved during follow-up in both treatment groups, without significant intergroup differences at last observation (1.20 mg/dL [1.10–1.30] vs. 1.20 mg/dL [0.80–1.40]). The median relative reduction in periaortic mass thickness was 41.2% (24.45–53.95). No significant differences in overall safety outcomes were observed. In this real-world cohort of patients with RPF, intensive intravenous immunosuppressive regimens were not associated with superior treatment effectiveness compared with less intensive oral therapies. These findings support an individualized approach to treatment selection in RPF, taking disease severity, renal involvement and patient-specific factors into account. Prospective studies in larger cohorts are needed to further define optimal long-term management strategies for this rare disease.
- 31 May 2022
- Published by Medical Communications Sp. z.o.o. in Pediatria i Medycyna Rodzinna
- Vol. 18 (1) , 70-77
An assessment of short- and long-term efficacy of local corticosteroid injection in patients with lateral epicondylitis
Aim of the study: An assessment of short- and long-term efficacy of local corticosteroid injection in patients with lateral epicondylitis (tennis elbow) based on The Disabilities of the Aim, Shoulder and Hand (DASH) questionnaire and Visual Analogue Scale (VAS), as well as an assessment of long-term treatment efficacy depending on baseline ultrasound disease activity. Materials and methods: A total of 32 patients presenting with tennis elbow and increased blood flow on ultrasound who were treated with local corticosteroid injection were included in the study. Baseline increase in blood flow, pain severity, upper limb function and the subjective response to treatment at 2 weeks (short-term outcomes) and 6 months (long-term outcomes) were assessed. Results: Short-term improvement was achieved in all patients. Long-term improvement was observed in 24 (75%) patients with lower baseline DASH and VAS. Long-term improvement was achieved in 15 (94%) patients in the group with low to moderate baseline disease activity on power Doppler ultrasound (16 patients) and in only 9 (54%) patients in the group with high baseline Doppler disease activity (16 patients). Conclusions: Local corticosteroid injection in patients with tennis elbow who present with increased baseline vascularity on ultrasound seems show short-term efficacy. Negative long-term prognostic factors seem to include significantly increased baseline vascularisation and high baseline DASH and VAS scores. Therefore, it seems reasonable to evaluate these factors before treatment onset, and if abnormalities are found, intensification of treatment or switch to another therapeutic option should be considered.
- 31 May 2022
- Published by Medical Communications Sp. z.o.o. in Pediatria i Medycyna Rodzinna
- Vol. 18 (1) , 70-77
An assessment of short- and long-term efficacy of local corticosteroid injection in patients with lateral epicondylitis
Aim of the study: An assessment of short- and long-term efficacy of local corticosteroid injection in patients with lateral epicondylitis (tennis elbow) based on The Disabilities of the Aim, Shoulder and Hand (DASH) questionnaire and Visual Analogue Scale (VAS), as well as an assessment of long-term treatment efficacy depending on baseline ultrasound disease activity. Materials and methods: A total of 32 patients presenting with tennis elbow and increased blood flow on ultrasound who were treated with local corticosteroid injection were included in the study. Baseline increase in blood flow, pain severity, upper limb function and the subjective response to treatment at 2 weeks (short-term outcomes) and 6 months (long-term outcomes) were assessed. Results: Short-term improvement was achieved in all patients. Long-term improvement was observed in 24 (75%) patients with lower baseline DASH and VAS. Long-term improvement was achieved in 15 (94%) patients in the group with low to moderate baseline disease activity on power Doppler ultrasound (16 patients) and in only 9 (54%) patients in the group with high baseline Doppler disease activity (16 patients). Conclusions: Local corticosteroid injection in patients with tennis elbow who present with increased baseline vascularity on ultrasound seems show short-term efficacy. Negative long-term prognostic factors seem to include significantly increased baseline vascularisation and high baseline DASH and VAS scores. Therefore, it seems reasonable to evaluate these factors before treatment onset, and if abnormalities are found, intensification of treatment or switch to another therapeutic option should be considered.
- Open Access
- 7 March 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (5) , 3136
Age, Cognitive Factors, and Acceptance of Living with the Disease in Rheumatoid Arthritis: The Short-Term Perspective
Rheumatoid arthritis is a chronic inflammatory disease leading to disability, reduced quality of life, and severe depressive symptoms. Theoretical models and research emphasize the importance of cognitive factors such as illness-related beliefs and cognitive appraisals in the process of adapting to life with a chronic disease. Objectives: The aim of this study was to analyze the role of age, disease duration, and cognitive factors in the level of acceptance of life with rheumatoid arthritis and determine the factors responsible for short-term (one week) changes without the use of interventions. We also assessed differences in predictors between rheumatoid arthritis, vascular diseases, and diabetes. Methods: Data were collected using a panel study. The first part of the analysis included 83 participants who declared a medical diagnosis of rheumatoid arthritis. In the second part of the analysis, in addition to people with rheumatoid arthritis (69 participants), two control groups were also included: diabetes (n = 26) and vascular disease (n = 26). The analysis examined basic sociodemographic and clinical data, cognitive appraisals, illness-related beliefs, and acceptance of living with the disease twice in one week. Results: The relationship between age and levels of acceptance of living with the disease was cubic, but the groups distinguished based on age and disease duration did not differ in terms of the analyzed variables. Cognitive appraisals (both baseline and changes over one week) were responsible for changes in acceptance of living with the disease, although other variables (sociodemographic, clinical, and illness-related beliefs) also played a role. The predictors of change in acceptance of living with the disease differed between analyzed diagnoses. Conclusions: Cognitive factors are an important aspect of the adaptation process to living with an illness. Potential clinical applications and future directions of research are discussed.
- 7 March 2022
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 19 (5) , 3136
Open AccessAge, Cognitive Factors, and Acceptance of Living with the Disease in Rheumatoid Arthritis: The Short-Term Perspective
Rheumatoid arthritis is a chronic inflammatory disease leading to disability, reduced quality of life, and severe depressive symptoms. Theoretical models and research emphasize the importance of cognitive factors such as illness-related beliefs and cognitive appraisals in the process of adapting to life with a chronic disease. Objectives: The aim of this study was to analyze the role of age, disease duration, and cognitive factors in the level of acceptance of life with rheumatoid arthritis and determine the factors responsible for short-term (one week) changes without the use of interventions. We also assessed differences in predictors between rheumatoid arthritis, vascular diseases, and diabetes. Methods: Data were collected using a panel study. The first part of the analysis included 83 participants who declared a medical diagnosis of rheumatoid arthritis. In the second part of the analysis, in addition to people with rheumatoid arthritis (69 participants), two control groups were also included: diabetes (n = 26) and vascular disease (n = 26). The analysis examined basic sociodemographic and clinical data, cognitive appraisals, illness-related beliefs, and acceptance of living with the disease twice in one week. Results: The relationship between age and levels of acceptance of living with the disease was cubic, but the groups distinguished based on age and disease duration did not differ in terms of the analyzed variables. Cognitive appraisals (both baseline and changes over one week) were responsible for changes in acceptance of living with the disease, although other variables (sociodemographic, clinical, and illness-related beliefs) also played a role. The predictors of change in acceptance of living with the disease differed between analyzed diagnoses. Conclusions: Cognitive factors are an important aspect of the adaptation process to living with an illness. Potential clinical applications and future directions of research are discussed.
- Open Access
- 7 December 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (12) , 2290
Early Myocardial Changes in Patients with Rheumatoid Arthritis without Known Cardiovascular Diseases—A Comprehensive Cardiac Magnetic Resonance Study
Clinically silent cardiac disease is frequently observed in rheumatoid arthritis (RA), and cardiovascular complications are the leading cause of mortality in RA. We sought to evaluate the myocardium of young RA patients without known cardiac disease using cardiac magnetic resonance (CMR), including T1/T2 mapping sequences. Eighteen RA patients (median age 41 years, 83% females) mainly with low disease activity or in remission and without any known cardiovascular disease were prospectively included to undergo CMR. A control group consisted of 10 sex- and age-matched patients without RA or any known structural cardiovascular disease. Heart chambers size and left/right ventricular systolic function were similar in patients with RA and controls. Signs of myocardial oedema were present in up to 39% of RA patients, including T2 time above cut-off value in 7 patients (39%) in comparison to none of the controls (p = 0.003) and T2 signal intensity ratio above the cut-off value in 6 patients (33%) and in none of the controls (p = 0.06). Extracellular volume was similar in both groups signifying a lack of diffuse fibrosis in studied group of RA patients. There were also no signs of late gadolinium enhancement (LGE) in either group except for one patient with RA who was found to have prior silent myocardial infarction. No correlation was found between markers of disease severity and markers of oedema observed on CMR in patients with RA. Nevertheless, patients with increased T2 time (≥50 ms) were more likely to have X-ray erosions (p = 0.02) and a longer duration between symptom onset and diagnosis (p = 0.02). Finally, there were no significant arrhythmias on 24-h ECG Holter monitoring in RA patients. CMR features of myocardial oedema without signs of myocardial fibrosis were found in 39% of young RA patients without known heart disease or cardiac symptoms. Presence of myocardial oedema was associated with X-ray erosions and a longer duration between symptom onset and diagnosis. The clinical significance of the observed early myocardial changes accompanying RA requires additional studies.
- 7 December 2021
- Published by MDPI AG in Diagnostics
- Vol. 11 (12) , 2290
Open AccessEarly Myocardial Changes in Patients with Rheumatoid Arthritis without Known Cardiovascular Diseases—A Comprehensive Cardiac Magnetic Resonance Study
Clinically silent cardiac disease is frequently observed in rheumatoid arthritis (RA), and cardiovascular complications are the leading cause of mortality in RA. We sought to evaluate the myocardium of young RA patients without known cardiac disease using cardiac magnetic resonance (CMR), including T1/T2 mapping sequences. Eighteen RA patients (median age 41 years, 83% females) mainly with low disease activity or in remission and without any known cardiovascular disease were prospectively included to undergo CMR. A control group consisted of 10 sex- and age-matched patients without RA or any known structural cardiovascular disease. Heart chambers size and left/right ventricular systolic function were similar in patients with RA and controls. Signs of myocardial oedema were present in up to 39% of RA patients, including T2 time above cut-off value in 7 patients (39%) in comparison to none of the controls (p = 0.003) and T2 signal intensity ratio above the cut-off value in 6 patients (33%) and in none of the controls (p = 0.06). Extracellular volume was similar in both groups signifying a lack of diffuse fibrosis in studied group of RA patients. There were also no signs of late gadolinium enhancement (LGE) in either group except for one patient with RA who was found to have prior silent myocardial infarction. No correlation was found between markers of disease severity and markers of oedema observed on CMR in patients with RA. Nevertheless, patients with increased T2 time (≥50 ms) were more likely to have X-ray erosions (p = 0.02) and a longer duration between symptom onset and diagnosis (p = 0.02). Finally, there were no significant arrhythmias on 24-h ECG Holter monitoring in RA patients. CMR features of myocardial oedema without signs of myocardial fibrosis were found in 39% of young RA patients without known heart disease or cardiac symptoms. Presence of myocardial oedema was associated with X-ray erosions and a longer duration between symptom onset and diagnosis. The clinical significance of the observed early myocardial changes accompanying RA requires additional studies.
- Open Access
- 28 October 2020
- Published by Springer Nature in Rheumatology International
- Vol. 41 (1) , 139-145
Trends in psoriatic arthritis epidemiology in Poland
Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis, usually seronegative and associated with psoriasis (Ps). The prevalence and incidence of psoriatic arthritis show strong ethnic and geographic variations. The aim of the study was to assess the epidemiological trends in psoriatic arthritis in Poland. The National Health Fund (NHF) database for the period 2008–2018 was analyzed. PsA was defined as ICD-10 codes L40.5, M07, M07.0, M07.1, M07.2 and M07.3, while psoriasis as ICD-10 codes L40 and L40.X (L40.0 to L40.9). A steady increase in the number of PsA patients (from 16,790 to 32,644) and in PsA recorded prevalence (from 38.47 per 100,000 in 2008 to 73.11 per 100,000 in 2018) was observed between 2008 and 2018. The PsA/Ps ratio increased to a similar extent (from 8.3 to 17.5%). The percentage of PsA patients receiving rehabilitation services remained constant throughout the observation period (mean: 17.35%; range 16.7–18.9%). The study showed a steady and continuous increase in PsA recorded prevalence. A simultaneous increase in the PsA/Ps ratio suggests that the main reason for the observed trend is greater disease detection .
- 28 October 2020
- Published by Springer Nature in Rheumatology International
- Vol. 41 (1) , 139-145
Open AccessTrends in psoriatic arthritis epidemiology in Poland
Psoriatic arthritis (PsA) is a heterogeneous inflammatory arthritis, usually seronegative and associated with psoriasis (Ps). The prevalence and incidence of psoriatic arthritis show strong ethnic and geographic variations. The aim of the study was to assess the epidemiological trends in psoriatic arthritis in Poland. The National Health Fund (NHF) database for the period 2008–2018 was analyzed. PsA was defined as ICD-10 codes L40.5, M07, M07.0, M07.1, M07.2 and M07.3, while psoriasis as ICD-10 codes L40 and L40.X (L40.0 to L40.9). A steady increase in the number of PsA patients (from 16,790 to 32,644) and in PsA recorded prevalence (from 38.47 per 100,000 in 2008 to 73.11 per 100,000 in 2018) was observed between 2008 and 2018. The PsA/Ps ratio increased to a similar extent (from 8.3 to 17.5%). The percentage of PsA patients receiving rehabilitation services remained constant throughout the observation period (mean: 17.35%; range 16.7–18.9%). The study showed a steady and continuous increase in PsA recorded prevalence. A simultaneous increase in the PsA/Ps ratio suggests that the main reason for the observed trend is greater disease detection .
- 4 December 2019
- Published by Springer Nature in Rheumatology International
- Vol. 40 (2) , 323-330
Prevalence of axial spondyloarthritis in Poland
The prevalence of axial spondyloarthritis (axSpA) in the published data varies significantly. Two types of axSpA can be distinguished depending upon the presence of abnormalities consistent with sacroiliitis on plain radiography: ankylosing spondylitis (AS) and nonradiographic axial SpA (nr-axSpA). The aim of this study is to perform a retrospective analysis of axSpA prevalence in Poland in the years 2008–2017. The National Health Fund (NHF) database for the period 2008–2017 was analysed. Data of all patients with the ICD-10 codes M46 (M46.1, M46.8, M46.9) or M45 (further named other inflammatory spondylopathies—OIS and AS, respectively) as the main or co-existing diagnosis were extracted and analysed. The AS prevalence was stable during the period under examination amounting to approximately 0.083%, while the OIS prevalence increased from 0.036 to 0.059%. For both men and women, the AS prevalence increased with age, reaching a maximum around the age of 70; however, in men, a marked increase in prevalence was observed earlier as compared to women (20–24 vs. 40–44 years, respectively). The OIS prevalence also increased with age; however, the maximum was reached earlier as in case of AS. Moreover, a sharp increase in OIS prevalence occurred earlier than in AS (15–19 years) with no difference between sexes. In Poland, approximately 0.1% of the population suffers from AS—the prevalence remained stable over the last decade. The prevalence of OIS increased markedly over the studied period which presumably reflects an increasing prevalence of nr-axSpA as the effect of the introduction of ASAS classification criteria for axSpA.
- 4 December 2019
- Published by Springer Nature in Rheumatology International
- Vol. 40 (2) , 323-330
Prevalence of axial spondyloarthritis in Poland
The prevalence of axial spondyloarthritis (axSpA) in the published data varies significantly. Two types of axSpA can be distinguished depending upon the presence of abnormalities consistent with sacroiliitis on plain radiography: ankylosing spondylitis (AS) and nonradiographic axial SpA (nr-axSpA). The aim of this study is to perform a retrospective analysis of axSpA prevalence in Poland in the years 2008–2017. The National Health Fund (NHF) database for the period 2008–2017 was analysed. Data of all patients with the ICD-10 codes M46 (M46.1, M46.8, M46.9) or M45 (further named other inflammatory spondylopathies—OIS and AS, respectively) as the main or co-existing diagnosis were extracted and analysed. The AS prevalence was stable during the period under examination amounting to approximately 0.083%, while the OIS prevalence increased from 0.036 to 0.059%. For both men and women, the AS prevalence increased with age, reaching a maximum around the age of 70; however, in men, a marked increase in prevalence was observed earlier as compared to women (20–24 vs. 40–44 years, respectively). The OIS prevalence also increased with age; however, the maximum was reached earlier as in case of AS. Moreover, a sharp increase in OIS prevalence occurred earlier than in AS (15–19 years) with no difference between sexes. In Poland, approximately 0.1% of the population suffers from AS—the prevalence remained stable over the last decade. The prevalence of OIS increased markedly over the studied period which presumably reflects an increasing prevalence of nr-axSpA as the effect of the introduction of ASAS classification criteria for axSpA.
- Open Access
- 29 October 2019
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 28 (11) , 1545-1553
Quality of life and clinical outcomes in Polish patients with high activity rheumatoid arthritis treated with leflunomide (Arava®) in Therapeutic Program: A retrospective analysis of data from the PLUS study
Rheumatoid arthritis (RA) is a chronic autoimmune disease. Therapy is based on disease-modifying agents. Methotrexate (MTX) is used in first-line therapy and, in the case of failure, its alternatives include leflunomide, which was recommended in Poland within the National Health Fund Therapeutic Program. The purpose of the study was to evaluate the parameters of quality of life of Polish patients with high RA activity during treatment with leflunomide. Additional aims were to evaluate the effectiveness and safety of treatment. We performed a retrospective analysis of the data from the PLUS study. The PLUS study comprised 887 adult patients from 30 centers. During the study patients received leflunomide in a maintenance dose of 20 mg or 10 mg once daily. Before the study, 100 mg of leflunomide had been administered daily for 3 days, followed by a maintenance dose of 20 mg/day or 10 mg/day for at least a month before enrollment. The PLUS study observation time was up to 12 months with 1 control visit every 3 months. The patients' quality of life was assessed with Health Assessment Questionnaire Disability Index (HAQ-DI). Erythrocyte sedimentation rate (ESR), Disease Activity Score (DAS28) and CRP (C-reactive protein) concentration were used to assess the disease activity. Six hundred seventy-nine patients completed the study. The HAQ-DI decreased after 3 months of observation (mean value 1.46 vs baseline 1.63; p = 0.001) and remained stable. The percentage of patients with HAQ-DI less than 1 and greater than 2 increased from 12.2% to 17.8% and decreased from 33.2% to 20.3%, respectively (p < 0.0001); DAS28 progressively decreased on subsequent visits. C-reactive protein and ESR decreased after 3 months and remained stable. Adverse events were observed in 4.4% of patients. Treatment with standard leflunomide doses is safe and allows for significant clinical improvement.
- 29 October 2019
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 28 (11) , 1545-1553
Open AccessQuality of life and clinical outcomes in Polish patients with high activity rheumatoid arthritis treated with leflunomide (Arava®) in Therapeutic Program: A retrospective analysis of data from the PLUS study
Rheumatoid arthritis (RA) is a chronic autoimmune disease. Therapy is based on disease-modifying agents. Methotrexate (MTX) is used in first-line therapy and, in the case of failure, its alternatives include leflunomide, which was recommended in Poland within the National Health Fund Therapeutic Program. The purpose of the study was to evaluate the parameters of quality of life of Polish patients with high RA activity during treatment with leflunomide. Additional aims were to evaluate the effectiveness and safety of treatment. We performed a retrospective analysis of the data from the PLUS study. The PLUS study comprised 887 adult patients from 30 centers. During the study patients received leflunomide in a maintenance dose of 20 mg or 10 mg once daily. Before the study, 100 mg of leflunomide had been administered daily for 3 days, followed by a maintenance dose of 20 mg/day or 10 mg/day for at least a month before enrollment. The PLUS study observation time was up to 12 months with 1 control visit every 3 months. The patients' quality of life was assessed with Health Assessment Questionnaire Disability Index (HAQ-DI). Erythrocyte sedimentation rate (ESR), Disease Activity Score (DAS28) and CRP (C-reactive protein) concentration were used to assess the disease activity. Six hundred seventy-nine patients completed the study. The HAQ-DI decreased after 3 months of observation (mean value 1.46 vs baseline 1.63; p = 0.001) and remained stable. The percentage of patients with HAQ-DI less than 1 and greater than 2 increased from 12.2% to 17.8% and decreased from 33.2% to 20.3%, respectively (p < 0.0001); DAS28 progressively decreased on subsequent visits. C-reactive protein and ESR decreased after 3 months and remained stable. Adverse events were observed in 4.4% of patients. Treatment with standard leflunomide doses is safe and allows for significant clinical improvement.
- 12 November 2018
- Published by Springer Nature in Rheumatology International
- Vol. 39 (2) , 301-310
Comparison of non-invasive assessment of arrhythmias, conduction disturbances and cardiac autonomic tone in systemic sclerosis and systemic lupus erythematosus
Systemic sclerosis (SSc) and systemic lupus erythematosus (SLE) are connective tissue diseases presenting cardiac complications including different arrhythmias, then direct electrocardiographic comparison may be useful in everyday clinical decision making. We examined 86 adult SSc patients, 76 with SLE and 45 healthy controls. Among other examinations all subjects underwent 24-h Holter monitoring with time-domain heart rate variability and heart rate turbulence evaluation. Patients with various co-existing conditions which might markedly influence arrhythmias and autonomic modulation were excluded from further analysis (SSc n = 12, SLE n = 6). Finally, 76 SSc and 70 SLE subjects were eligible for this study, mean age 51.9 ± 13.1 and 46.5 ± 12.7 years (p = 0.11), with median disease duration 6.0 and 8.5 years (p = 0.15), respectively. As compared to SLE, patients with SSc were characterised by more frequent incidence of various supraventricular and ventricular arrhythmias. As compared to SSc, patients with SLE presented prolonged corrected QT intervals and also significant correlations between corrected QT length and heart rate variability indices. Both SSc and SLE subjects presented impaired sympathetic cardiac autonomic modulation, while indices associated with parasympathetic activity in SLE were not diminished. Disease duration was not associated with arrhythmias’ occurrence (except for ventricular tachycardia in SSc, p = 0.02) and also with autonomic function in both groups of patients. Patients with SSc and SLE differ in terms of arrhythmias, conduction disturbances and cardiac autonomic tone. Regular Holter monitoring should be considered as a part of routine evaluation in connective tissue diseases patients, especially in systemic sclerosis.
- 12 November 2018
- Published by Springer Nature in Rheumatology International
- Vol. 39 (2) , 301-310
Comparison of non-invasive assessment of arrhythmias, conduction disturbances and cardiac autonomic tone in systemic sclerosis and systemic lupus erythematosus
Systemic sclerosis (SSc) and systemic lupus erythematosus (SLE) are connective tissue diseases presenting cardiac complications including different arrhythmias, then direct electrocardiographic comparison may be useful in everyday clinical decision making. We examined 86 adult SSc patients, 76 with SLE and 45 healthy controls. Among other examinations all subjects underwent 24-h Holter monitoring with time-domain heart rate variability and heart rate turbulence evaluation. Patients with various co-existing conditions which might markedly influence arrhythmias and autonomic modulation were excluded from further analysis (SSc n = 12, SLE n = 6). Finally, 76 SSc and 70 SLE subjects were eligible for this study, mean age 51.9 ± 13.1 and 46.5 ± 12.7 years (p = 0.11), with median disease duration 6.0 and 8.5 years (p = 0.15), respectively. As compared to SLE, patients with SSc were characterised by more frequent incidence of various supraventricular and ventricular arrhythmias. As compared to SSc, patients with SLE presented prolonged corrected QT intervals and also significant correlations between corrected QT length and heart rate variability indices. Both SSc and SLE subjects presented impaired sympathetic cardiac autonomic modulation, while indices associated with parasympathetic activity in SLE were not diminished. Disease duration was not associated with arrhythmias’ occurrence (except for ventricular tachycardia in SSc, p = 0.02) and also with autonomic function in both groups of patients. Patients with SSc and SLE differ in terms of arrhythmias, conduction disturbances and cardiac autonomic tone. Regular Holter monitoring should be considered as a part of routine evaluation in connective tissue diseases patients, especially in systemic sclerosis.
- Open Access
- 29 October 2018
- Published by Springer Nature in Rheumatology International
- Vol. 39 (2) , 327-336
Common atherosclerosis genetic risk factors and subclinical atherosclerosis in rheumatoid arthritis: the relevance of disease duration
Rheumatoid arthritis (RA) is a common systemic autoimmune disease characterized by increased cardiovascular morbidity. Several previous studies assessed associations between common atherosclerotic genetic risk factors and subclinical atherosclerosis (SA) in RA patients, yet most of them gave negative results. We undertook a cross-sectional study to evaluate the association between previously reported SNPs and subclinical atherosclerosis in a cohort of Polish RA patients. 29 SNPs associated with atherosclerosis in general population were genotyped in 289 RA patients: 116 patients with SA (increased carotid intima–media thickness and/or presence of carotid plaque) and 173 patients without SA. To assess the cumulative effect of SNPs we calculated 3 weighted genetic risk scores: GRSIMT, GRSCP and GRSCAD, comprising intima–media thickness-associated SNPs, carotid plaque-associated SNPs and coronary artery disease-associated SNPs, respectively. None of the SNPs showed a significant association with SA. However, we found an association between SA and GRSIMT. Interestingly, this association was limited to patients with short disease duration (P = 0.00004 vs. P > 0.5, for comparison of GRSIMT among patients within the 1st quartile of disease duration vs. others, respectively). Patients within the 1st quartile of disease duration were more frequently disease modifying anti-rheumatic drugs (DMARDs)-naïve and less frequently treated with biologics. Our study suggests that in patients with early RA subclinical atherosclerosis may be driven by similar genetic factors as in general population, while in long-lasting disease, the role common genetic risk factors may decrease. Possibly, this effect may be due to the influence of DMARDs.
- 29 October 2018
- Published by Springer Nature in Rheumatology International
- Vol. 39 (2) , 327-336
Open AccessCommon atherosclerosis genetic risk factors and subclinical atherosclerosis in rheumatoid arthritis: the relevance of disease duration
Rheumatoid arthritis (RA) is a common systemic autoimmune disease characterized by increased cardiovascular morbidity. Several previous studies assessed associations between common atherosclerotic genetic risk factors and subclinical atherosclerosis (SA) in RA patients, yet most of them gave negative results. We undertook a cross-sectional study to evaluate the association between previously reported SNPs and subclinical atherosclerosis in a cohort of Polish RA patients. 29 SNPs associated with atherosclerosis in general population were genotyped in 289 RA patients: 116 patients with SA (increased carotid intima–media thickness and/or presence of carotid plaque) and 173 patients without SA. To assess the cumulative effect of SNPs we calculated 3 weighted genetic risk scores: GRSIMT, GRSCP and GRSCAD, comprising intima–media thickness-associated SNPs, carotid plaque-associated SNPs and coronary artery disease-associated SNPs, respectively. None of the SNPs showed a significant association with SA. However, we found an association between SA and GRSIMT. Interestingly, this association was limited to patients with short disease duration (P = 0.00004 vs. P > 0.5, for comparison of GRSIMT among patients within the 1st quartile of disease duration vs. others, respectively). Patients within the 1st quartile of disease duration were more frequently disease modifying anti-rheumatic drugs (DMARDs)-naïve and less frequently treated with biologics. Our study suggests that in patients with early RA subclinical atherosclerosis may be driven by similar genetic factors as in general population, while in long-lasting disease, the role common genetic risk factors may decrease. Possibly, this effect may be due to the influence of DMARDs.